Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies.

With the advent of novel therapeutic agents including factor concentrates with ultra-long half-life and improved FVIIIa mimetics aimed at raising the bar of protection into the non-hemophilic range redefinition of haemophilia treatment goals is eagerly needed.